Kenox Announces Clinical Manufacturing Readiness for Nasal and Inhaled Drug Products

On Mar 5, 2026

Princeton-based Kenox Pharmaceuticals Inc. (Kenox), a fast‑growing contract development and manufacturing organization (CDMO) dedicated exclusively to Orally Inhaled and Nasal Drug Products (OINDPs) and Ophthalmic Drug Products, announced that it is now fully Clinical Manufacturing Ready. The company has also expanded its GMP analytical testing capabilities in OINDPs, including in vitro bioequivalence (IVBE) testing, to support innovators advancing nasal and inhaled therapies.

“Achieving clinical manufacturing readiness is a major milestone for Kenox,” said Sitaram Velaga, founder, president, and CEO of Kenox. “Our goal has always been to help partners reach the clinic faster and with greater confidence. By integrating development, GMP testing—including IVBE—and clinical manufacturing under one roof, we are significantly de‑risking early‑stage programs while delivering the speed, flexibility, and quality that innovative OINDP products demand.”

Kenox supports small‑scale fill–finish operations for small molecules, peptides, and biologics, with batch sizes ranging from hundreds to a few thousand units, ideally suited for Phase I and Phase II clinical trials.

Kenox’s specialized expertise spans nebulizers, soft mist inhalers (SMIs), nasal sprays, and dry powder inhalers (DPIs), supported by robust analytical and formulation development, comprehensive OINDP performance testing, IVBE studies, and regulatory support packages. These integrated capabilities help de‑risk development, shorten timelines, and provide a true one‑stop solution from feasibility through clinical supply and bioequivalence support.

With its expanded capabilities, Kenox is positioned to support programs across a broad range of therapeutic areas, including CNS indications leveraging nose‑to‑brain delivery (psychiatry, Alzheimer’s disease, ALS, Parkinson’s disease, traumatic brain injury), pulmonary conditions (asthma, COPD, PAH, IPF), pain management, and select rare diseases. Kenox welcomes partnership discussions to help accelerate time to clinic and time to market.

To access more business news, visit NJB News Now.

Related Articles: